Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1371/journal.ppat.1010343 http://scihub22266oqcxt.onion/10.1371/journal.ppat.1010343 35176124!8890723!35176124     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 269.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       PLoS+Pathog 2022 ; 18 (2): e1010343 Nephropedia Template TP {{tp|p=35176124|t=2022. Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung |pdf=|usr=}}{{35176124}} gab.com Text Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung JO: PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=35176124 #FOAvip The continuous emergence of severe acute respiratory coronavirus 2 (SARS-CoV-2) variants and the increasing number of breakthrough infection cases among vaccinated people support the urgent need for research and development of antiviral drugs. Viral entry is an intriguing target for antiviral drug development. We found that diltiazem, a blocker of the L-type calcium channel Cav1.2 pore-forming subunit (Cav1.2 alpha1c) and an FDA-approved drug, inhibits the binding and internalization of SARS-CoV-2, and decreases SARS-CoV-2 infection in cells and mouse lung. Cav1.2 alpha1c interacts with SARS-CoV-2 spike protein and ACE2, and affects the attachment and internalization of SARS-CoV-2. Our finding suggests that diltiazem has potential as a drug against SARS-CoV-2 infection and that Cav1.2 alpha1c is a promising target for antiviral drug development for COVID-19. Twit Text FOAVip Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung ????PLoS Pathog http://www.kidney.de/pget.php?&tw=1&pmid=35176124 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=35176124 #FOAvip English Wikipedia <ref>{{Cite pmid|35176124}}</ref> Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung #MMPMID35176124 Wang X; Luo J; Wen Z; Shuai L; Wang C; Zhong G; He X; Cao H; Liu R; Ge J; Hua R; Sun Z; Wang X; Wang J; Bu Z PLoS Pathog 2022[Feb]; 18 (2): e1010343 PMID35176124show ga The continuous emergence of severe acute respiratory coronavirus 2 (SARS-CoV-2) variants and the increasing number of breakthrough infection cases among vaccinated people support the urgent need for research and development of antiviral drugs. Viral entry is an intriguing target for antiviral drug development. We found that diltiazem, a blocker of the L-type calcium channel Cav1.2 pore-forming subunit (Cav1.2 alpha1c) and an FDA-approved drug, inhibits the binding and internalization of SARS-CoV-2, and decreases SARS-CoV-2 infection in cells and mouse lung. Cav1.2 alpha1c interacts with SARS-CoV-2 spike protein and ACE2, and affects the attachment and internalization of SARS-CoV-2. Our finding suggests that diltiazem has potential as a drug against SARS-CoV-2 infection and that Cav1.2 alpha1c is a promising target for antiviral drug development for COVID-19. |*COVID-19 Drug Treatment[MESH] |*COVID-19/pathology/virology[MESH] |A549 Cells[MESH] |Animals[MESH] |Cells, Cultured[MESH] |Chlorocebus aethiops[MESH] |Diltiazem/*pharmacology/therapeutic use[MESH] |Disease Models, Animal[MESH] |Female[MESH] |HEK293 Cells[MESH] |HeLa Cells[MESH] |Humans[MESH] |Lung/*drug effects/pathology/virology[MESH] |Mice[MESH] |Mice, Inbred BALB C[MESH] |Mice, Inbred C57BL[MESH] |Mice, Transgenic[MESH] |SARS-CoV-2/*drug effects/physiology[MESH] |Vero Cells[MESH] |Virus Attachment/drug effects[MESH]Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and (epmc).pdf DeepDyve Pubget Overpricing